The main purpose of this study is to learn how transcranial magnetic stimulation (TMS) helps improve negative symptoms of schizophrenia. These 'negative symptoms' include anhedonia (the inability to enjoy things), low motivation, and decreased facial expression. TMS is a noninvasive way of stimulating the brain. TMS uses a magnetic field to cause changes in activity in the brain. The magnetic field is produced by a coil that is held next to the scalp. In this study we will be stimulating the brain to learn more about how TMS may improve these symptoms from schizophrenia.
Name: repetitive Transcranial Magnetic Stimulation (rTMS)
Description: We will evaluate the effect of sham vs active rTMS on negative symptom severity in the group with Cerebellar targeted rTMS and in the group with DLPFC targeted rTMS
Measure: Change in Negative Symptom Severity Time: Before treatment (Baseline) and 1 week post treatmentDescription: We will evaluate the effect of sham vs active rTMS on cerebellar-prefrontal cortex functional connectivity in the group with Cerebellar targeted rTMS and in the group with DLPFC targeted rTMS
Measure: Change in Cerebellar - Prefrontal Functional Connectivity Time: Before treatment (Baseline) and 1 week post treatmentDescription: We will evaluate the effect of sham vs active rTMS on the frequency and severity of auditory hallucinations in the group with Cerebellar targeted rTMS and in the group with DLPFC targeted rTMS
Measure: Change in Auditory Hallucination Severity Time: Before treatment (Baseline) and 1 week post treatmentAllocation: Randomized
Parallel Assignment
There is one SNP
Hypothesis: Brain-derived neurotrophic factor (BDNF) homozygous val-allele carriers of the val66met BDNF gene will show greater response than met-carriers. --- val66met ---